IPH5201 plus Imfinzi in perioperative NSCLC looks better than some but not other historical studies.
ApexOnco Front Page
Recent articles
Daraxonrasib scores a plenary session late-breaker.
The group also discontinues a mystery asset, and a Tecentriq trial in periadjuvant lung cancer.
The line-up is revealed to include Merck & Co and J&J itself.
The latest onvansertib data, and an abrupt CEO departure, spook investors.
A phase 1 study of OKI-219 reads out imminently.
Bristol will test the bispecific in two new lung indications.
After Genmab’s exit two more ADCs enter human trials.
